© Borgis - Postępy Nauk Medycznych 4/2013, s. 262-266
*Magdalena Walicka1, Wojciech Bik2, Ewa Wolińska-Witort2, Ewa Marcinowska-Suchowierska1
Wpływ płci na stężenia adipokin oraz ich korelacje z insulinoopornością u pacjentów z otyłością olbrzymią
Gender dependent dimorphism in adipokines levels and its correlations with insulin resistance in extremely obese patients
1Internal, Family Medicine and Metabolic Bone Disease Department, Medical Centre of Postgraduate Education, Warsaw
Head of Department: prof. Ewa Marcinowska-Suchowierska, MD, PhD
2Department of Neuroendocrinology, Medical Centre of Postgraduate Education, Warsaw
Head of Department: Wojciech Bik, MD, PhD
Wprowadzenie. Otyłość łączy się z insulinoopornością, a insulinooporoność jest związana ze zmianami w zakresie stężeń adipokin. Zaobserwowano również różnice w stężeniach niektórych adipokin związane z płcią.
Cel pracy. Celem pracy była ocena wpływu płci na stężenia adiponektyny i jej frakcji, wisfatyny i waspiny oraz na ich korelacje z insulinoopornością u pacjentów z otyłością olbrzymią.
Materiał i metody. Do badania włączono 34 osoby z otyłością olbrzymią (BMI ≥ 40 kg/m2, 12 mężczyzn i 22 kobiety). U wszystkich oznaczono stężenia w surowicy krwi na czczo: glukozy, insuliny, adiponektyny i jej frakcji, wisfatyny, wapsiny oraz obliczono wskaźnik insulinooporności HOMA-IR.
Wyniki. Wskaźnik HOMA-IR był prawie dwukrotnie wyższy u mężczyzn niż u kobiet. U kobiet stwierdzono wyższe stężenia adiponektyny i jej frakcji HMW, leptyny i wisfatyny. Ujemną korelację między: stężeniem adiponektyny a insuliny, stężeniem adiponektyny a HOMA-IR, frakcją HMW adiponektyny a insuliną, frakcją HMW adiponektyny a HOMA-IR zaobserwowano tylko u kobiet. Dodatnią korelację między stężeniem leptyny a HOMA-IR zaobserwowano tylko u mężczyzn.
Wnioski. U pacjentów z otyłością olbrzymią występuje dymorfizm płciowy dotyczący stężeń adipokin oraz ich korelacji z insulinoopornością. Zjawisko to nie jest w pełni zrozumiałe ale może być związane z różnicami w zakresie dystrybucji tkanki tłuszczowej.
Introduction. Obesity is closely associated with insulin resistance, and insulin resistance is connected with altered adipokine levels. There are gender differences in some adipokines concentration.
Aim. The aim of this study was to evaluate sex-dependent differences in adiponectin fractions, visfatin and vaspin concentrations and gender dimorphism in association between this adipokines and insulin resistance in obesity.
Material and methods. Thirty four extremely obese (BMI ≥ 40 kg/m2) patients (12 male and 22 female) were enrolled in the study. In all subjects fasting serum glucose, insulin, adiponectin and its fractions, visfatin, vaspin concentration were measured and HOMA-IR was calculated.
Results. Men presented almost twofold higher HOMA-IR than women. Total adiponectin and HMW adiponectin, leptin and visfatin concentrations were higher in women than in men. Significant negative correlations between: total adiponectin and insulin, total adiponectin and HOMA-IR, HMW adiponectin and insulin, HMW adiponectin and HOMA-IR were observed only in female. Significant positive correlation between leptin and HOMA-IR was find only in male.
Conslusions. In extremely obese patients there is a gender dependent dimorphism in adipokines levels and their correlations with insulin resistance. This dimorphism is not fully understood and it might be due to different adipose tissue distribution.
After the past decade discoveries, adipose tissue is no longer regarded as a simple reservoir of energy, but rather as a fundamental endocrine gland of the human body. Adipocyte-derived bioactive substances, named adipokines, are able to influence on numerous physiological and pathological processes. Moreover, adipose tissue is also the largest organ in the whole body and possesses metabolic and endocrine functions. In details, by secreting adipokines, it plays a significant role in regulating lipid and carbohydrates homeostasis, and it is thought to be the major site of steroid metabolism. It influences on vascular function. Furthermore, adipokines mediate appetite and energy balance. Disturbed secretion of adipokines resulting from excessive accumulation of adipose tissue contributes to diabetes, hyperlipidaemia and hypertension. Obesity is closely associated with insulin resistance, and, on the other hand, insulin resistance is connected with altered adipokine levels (1).
Adiponectin is secreted mainly by adipocytes of the white adipose tissue. It increases insulin sensitivity, and reveals anti-inflammatory and anti-atherosclerotic action (2). Interestingly, lower adiponectin levels were found in obesity especially in visceral adiposity (3, 4). Adiponectin circulates in serum in different complexes of multimers, from low molecular weight (LMW) trimmers, through medium molecular weight (MMW) hexamers to high molecular weight (HMW) multimers. It is believed that dependently on the form of adiponectin, different physiologic properties of this adipokine are present (5). Recent clinical and experimental studies showed that HMW form of adiponectin possesses strong anti-diabetic and anti-atherogenic properties (6, 7).
Visfatin is expressed in many tissues although initially it was reported to be released by visceral adipose tissue (8). Primary studies showed that this adipokine activates insulin receptor and presents insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity (8). However, the results of further studies on the role of visfatin in glucose and lipid metabolism were contradictory (9, 10). Our current knowledge about the role of visfatin in the pathogenesis of obesity and metabolic syndrome is limited.
Vaspin (visceral adipose tissue-derived serpin; serpinA12) was originally identified as an adipokine, being predominantly secreted from visceral adipose tissue in Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of obesity and type 2 diabetes. Consistently, both higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance and type 2 diabetes in humans. However, the precise mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood yet (11, 12).
Leptin plays a key role in regulating energy intake and energy expenditure including appetite, hunger and metabolism. In physiological conditions, it reduces food intake on the brain level and enhances expenditure of energy, mainly by influencing on thermoregulation as increase in thermogenesis and metabolic rate were found (1). Besides, this adipokine is regarded as one of the most important adipose-derived hormones as pleiotropic effects of leptin have been reported. Previous studies indicated that human obesity is characterized by increased levels of circulating leptin. Despite the elevated leptin levels, which normally would be anticipated to reduce food intake and to decrease body fat, obese patients are insensitive to the action of leptin and continue to maintain increased amount of body fat (2).
Interestingly, there are gender differences seen in concentration of adipokines. Gender is a major determinant of plasma leptin concentration as women had approximately 40% higher leptin levels than men at any level of adiposity (13). Similarly, adiponectin levels are found to be greater in women (14, 15). Nevertheless, there are no available data concerning sex-dependent differences in adiponectin fractions, visfatin and vaspin concentrations. Finally, to our knowledge there is a lack of information about existing gender dimorphism in association between adiponectin fractions, visfatin, vaspin, leptin and insulin resistance in obesity.
MATERIAL AND METHODS
Thirty four extremely obese (BMI ≥ 40 kg/m2) patients (12 male and 22 female) were enrolled in the study. All individuals were Caucasians and were recruited among patients of Department of Family, Internal Medicine and Metabolic Bone Diseases, Orlowski Hospital, Centre of Postgraduate Medical Education in Warsaw, Poland. All patients were admitted to the hospital for internal examination prior to the bariatric surgery. Exclusion criteria from the study were as follows: acute endocrine dysfunction as well as chronic kidney and liver disease. None of examined subjects had a history of excessive alcohol consumption.
The study protocol was accepted by the Bioethical Committee of the Centre of Postgraduate Medical Education. Informed consent was obtained from all study participants.
Blood samples were obtained at 8.00 am after overnight fasting and were immediately centrifuged at 4°C and obtained plasma were stored at – 30°C for further analyses. Blood glucose concentration was measured by certified hospital laboratory applying standard clinical biochemistry methods. Insulin concentration was measured using IRMA methods (Immunotech, Czech Republic). Adiponectin and its fractions as well as c-terminal fragment of visfatin were estimated by EIA methods (ALPCO and Phoenix Pharmaceutical Inc., respectively). Plasma vaspin concentration was measured using ELISA kit (AdipoGen). Intra- and inter assay coefficient was below 10% for all investigated parameters. All adipokines and insulin levels were investigated in the Department of Neuroendocrinology, Centre of Postgraduate Medical Education in Warsaw.
In all subjects HOMA-IR was calculated according to the following formula: HOMA-IR = fasting glucose (mmol/dl) x fasting plasma insulin (μIU/ml)/22.5.
Statistica 6.1 was used for statistical analysis. Data are shown as means ± standard deviation (SD). The presence of normal distribution was analysed using Kolmogorow-Smirnoff test and differences in parametric variables were calculated with t-Student test. Non-parametric variables were analysed using Mann-Whitney U test. The Spearman test was applied to calculate correlations coefficients between estimated adipokines and biochemical parameters Significance level was defined as p < 0.05.
Data concerning clinical and biochemical parameters are presented in table 1. We found significant differences between extremely obese men and women in age, glucose levels and HOMA-IR. Men presented almost twofold higher HOMA-IR than women.
Table 1. Clinical and biochemical parameters of investigated groups.
(n = 12)
(n = 22)
|Age (y)||47.7 ± 7.1||39.6 ± 11.6||< 0.05|
|BMI (kg/m2)||45.6 ± 8.2||42.3 ± 5.5||ns|
|Glucose (mg/dl)||124.3 ± 39.5||96.8 ± 13.4||< 0.05|
|Insulin (μIU/ml)||28.8 ± 18.3||17.6 ± 9.4||ns|
|HOMA-IR||8.4 ± 4.8||4.3 ± 2.5||< 0.05|
ns – non significant
Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Płatny dostęp do wszystkich zasobów Czytelni Medycznej
1. Falcão-Pires I, Castro-Chaves P, Miranda-Silva D et al.: Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012; 15-16: 880-889.
2. Harwood HJ Jr: The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology 2012; 63: 57-75.
3. Kovacova Z, Tencerova M, Roussel B et al.: The impact of obesity on secretion of adiponectin multimeric isoforms differs in visceral and subcutaneous adipose tissue. Int J Obes (Lond) 2012; 36: 1360-1365.
4. Weyer C, Funahashi T, Tanaka S et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
5. McCourt HJ, Hunter SJ, Cardwell CR et al.: Adiponectin multimers, body weight and markers of cardiovascular risk in adolescence: Northern Ireland Young Hearts Project. Int J Obes (Lond) 2013; doi: 10.1038/ijo.2012.214.
6. von Eynatten M, Humpert PM, Bluemm A et al.: High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis 2008; 199: 123-128.
7. Wang W, Xing W, Zhang H et al.: Reduced high molecular weight adiponectin is an independent risk factor of cardiovascular lesions in hypercholesterolemic patients. Clin Endocrinol (Oxf) 2012; doi: 10.1111/j.1365-2265.2012.04444.x.
8. Fukuhara A, Matsuda M, Nishizawa M et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
9. Harasim E, Chabowski A, Górski J: Lack of downstream insulin-mimetic effects of visfatin/eNAMPT on glucose and fatty acid metabolism in skeletal muscles. Acta Physiol (Oxf) 2011; 202: 21-28.
10. Taşkesen D, Kirel B, Us T: Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81.
11. Blüher M: Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012; 41: 176-182.
12. Bik W, Baranowska-Bik A, Wolińska-Witrot E et al.: Vaspin plasma levels in extremely obese women. Post N Med 2012; 25: 67-71.
13. Saad MF, Damani S, Gingerich RL et al.: Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579-584.
14. Boyne MS, Bennett NR, Cooper RS et al.: Sex-differences in adiponectin levels and body fat distribution: longitudinal observation in Afro-Jamaicans. Diabetes Res Clin Pract 2010; 90: e33-36.
15. Andreasson AN, Undén AL, Elofsson S et al.: Leptin and adiponectin: distribution and associations with cardiovascular risk factors in men and women of the general population. Am J Hum Biol 2012; 24: 595-601.
16. Geer EB, Shen W: Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009; 6 (Suppl. 1): 60-75.
17. Lovejoy JC, Sainsbury A: Stock Conference 2008 Working Group. Sex differences in obesity and the regulation of energy homeostasis. Obes Rev 2009; 10: 154-167.
18. Kwon K, Jung SH, Choi C et al.: Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol 2005; 101: 385-390.
19. Indulekha K, Surendar J, Anjana RM et al.: Circulating levels of high molecular weight (HMW) adiponectin and total adiponectin in relation to fat distribution, oxidative stress and inflammation in Asian Indians. Dis Markers 2012; 33: 185-192.
20. Indulekha K, Anjana RM, Surendar J et al.: Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem 2011; 44 : 281-287.
21. Bidulescu A, Liu J, Hickson DA et al.: Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. BMC Cardiovasc Disord 2013; 13: 9.
22. Eglit T, Lember M, Ringmets I et al.: Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome. Eur J Endocrinol 2013; 168: 385-391.
23. Riestra P, Garcia-Anguita A, Ortega L et al.: Relationship of Adiponectin with Sex Hormone Levels in Adolescents. Horm Res Paediatr 2013 [Epub ahead of print].
24. Matsui S, Yasui T, Tani A et al.: Association of circulating adiponectin with testosterone in women during the menopausal transition. Maturitas 2012; 73: 255-260.
25. Merki-Feld GS, Imthurn B, Rosselli M et al.: Serum concentrations of high-molecular weight adiponectin and their association with sex steroids in premenopausal women. Metabolism 2011; 60:180-185.
26. Leung KC, Xu A, Craig ME et al.: Adiponectin isoform distribution in women – relationship to female sex steroids and insulin sensitivity. Metabolism 2009; 58: 239-245.
27. Morgan SA, Bringolf JB, Seidel ER: Visfatin expression is elevated in normal human pregnancy. Peptides 2008; 29: 1382-1289.
28. Zhou J, Seidel ER: Estrogens induce visfatin expression in 3T3-L1 cells. Peptides 2010; 31: 271-274.
29. Kowalska I, Straczkowski M, Nikolajuk A et al.: Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007; 22: 1824-1829.
30. Cicero AF, Magni P, Moré M et al.: Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the brisighella heart study. Int J Endocrinol 2011; 2011: 724-816.
31. Murdolo G, Nowotny B, Celi F et al.: Inflammatory adipokines high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal school children. PLoS One 2011; 6: e17264.
32. Seeger J, Ziegelmeier M, Bachmann A et al.: Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93: 247-251.
33. Esteghamati A, Mousavizadeh M, Noshad S et al:. Gender-dependent Effects of Metformin on Vaspin and Adiponectin in Type 2 Diabetes Patients: A Randomized Clinical Trial. Horm Metab Res 2012 [Epub ahead of print].